Literature DB >> 24692703

Endoplasmic reticulum stress response as a possible mechanism of cyclooxygenase-2-independent anticancer effect of celecoxib.

Wonjae Cha1, Seok-Woo Park, Tack-Kyun Kwon, J Hun Hah, Myung-Whun Sung.   

Abstract

BACKGROUND: We investigated whether the endoplasmic reticulum (ER) stress response could be a cyclooxygenase-2 (COX2)-independent mechanism of growth inhibition by celecoxib in a head and neck squamous cell carcinoma (HNSCC) cell line.
MATERIALS AND METHODS: We performed western blotting and reverse transcription polymerase chain reaction to analyze the expression of ER stress response-associated proteins C/EBP homologous protein (CHOP), glucose-regulated protein (GRP)-78 and X-box binding protein-1 (XBP1), after treatment of celecoxib in the SNU-1041 cell line. A 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was performed to determine the change in growth inhibition by celecoxib after inhibition of the ER stress pathway by CHOP small-interfering RNA (siRNA).
RESULTS: Celecoxib triggered an ER stress response in this HNSCC cell line as shown by activation of CHOP, GRP78 and XBP1. The inhibition of cell proliferation by celecoxib was effectively hindered with CHOP siRNA.
CONCLUSION: ER stress response could be a COX2-independent anticancer mechanism of celecoxib.

Entities:  

Keywords:  COX2; Celecoxib; endoplasmic reticulum stress response; head and neck cancer

Mesh:

Substances:

Year:  2014        PMID: 24692703

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  8 in total

Review 1.  Targeting the unfolded protein response in head and neck and oral cavity cancers.

Authors:  Daniel W Cole; Peter F Svider; Kerolos G Shenouda; Paul B Lee; Nicholas G Yoo; Thomas M McLeod; Sean A Mutchnick; George H Yoo; Randal J Kaufman; Michael U Callaghan; Andrew M Fribley
Journal:  Exp Cell Res       Date:  2019-05-07       Impact factor: 3.905

2.  Human Emotions on the Onset of Cardiovascular and Small Vessel Related Diseases.

Authors:  Chrisanthy Vlachakis; Konstantina Dragoumani; Sofia Raftopoulou; Meropi Mantaiou; Louis Papageorgiou; Spyridon Champeris Tsaniras; Vasileios Megalooikonomou; Dimitrios Vlachakis
Journal:  In Vivo       Date:  2018 Jul-Aug       Impact factor: 2.155

3.  Clinical benefit in recurrent glioblastoma from adjuvant NovoTTF-100A and TCCC after temozolomide and bevacizumab failure: a preliminary observation.

Authors:  Eric T Wong; Edwin Lok; Kenneth D Swanson
Journal:  Cancer Med       Date:  2015-01-26       Impact factor: 4.452

4.  IL-33 facilitates proliferation of colorectal cancer dependent on COX2/PGE2.

Authors:  Yongkui Li; Jie Shi; Shanshan Qi; Jian Zhang; Dong Peng; Zhenzhen Chen; Guobin Wang; Zheng Wang; Lin Wang
Journal:  J Exp Clin Cancer Res       Date:  2018-08-17

5.  Indomethacin-induced oxidative stress enhances death receptor 5 signaling and sensitizes tumor cells to adoptive T-cell therapy.

Authors:  Nada S Aboelella; Caitlin Brandle; Ogacheko Okoko; Md Yeashin Gazi; Zhi-Chun Ding; Hongyan Xu; Gregory Gorman; Roni Bollag; Marco L Davila; Locke J Bryan; David H Munn; Gary A Piazza; Gang Zhou
Journal:  J Immunother Cancer       Date:  2022-07       Impact factor: 12.469

6.  Endoplasmic Reticulum Stress Contributes to Indomethacin-Induced Glioma Apoptosis.

Authors:  Cheng-Yi Chang; Jian-Ri Li; Chih-Cheng Wu; Jiaan-Der Wang; Su-Lan Liao; Wen-Ying Chen; Wen-Yi Wang; Chun-Jung Chen
Journal:  Int J Mol Sci       Date:  2020-01-15       Impact factor: 5.923

7.  Endoplasmic Reticulum Stress-Induced Resistance to Doxorubicin Is Reversed by Mulberry Leaf Polyphenol Extract in Hepatocellular Carcinoma through Inhibition of COX-2.

Authors:  Mon-Yuan Yang; Cheng-Hsun Wu; Tung-Wei Hung; Chau-Jong Wang
Journal:  Antioxidants (Basel)       Date:  2019-12-26

Review 8.  Oxidative Stress in the Tumor Microenvironment and Its Relevance to Cancer Immunotherapy.

Authors:  Nada S Aboelella; Caitlin Brandle; Timothy Kim; Zhi-Chun Ding; Gang Zhou
Journal:  Cancers (Basel)       Date:  2021-02-27       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.